Additional Insights From Natalizumab Treatment In Ms

Additional Insights from Natalizumab Treatment in MS

Gavin Giovannoni

Insights into the latest research in MS

The Multiple Sclerosis Trust

Natalizumab versus anti-CD20 monoclonal antibodies in the treatment of MS

Benefits of SC natalizumab in MS

NEXT-MS: personalized extended interval dosing of natalizumab in RRMS

Impact of natalizumab on chronic active MS lesions

Updates on natalizumab and anti-CD20 antibodies for MS

Discovering markers of disease progression in patients with MS treated with natalizumab

Implications of extended dosing of natalizumab on wearing-off symptoms in MS patients

Safely switching from natalizumab to ocrelizumab in patients with MS at risk of PML

How Tysabri (natalizumab) Works in Relapsing Multiple Sclerosis

Bench to Bedside: Multiple Sclerosis and Tysabri, Part 1 - Ted Yednock

Science Communication Lab

Adverse events associated with natalizumab in MS and advice on mitigating them

What You Need to Know About Natalizumab (Tysabri®)

National MS Society

Bench to Bedside: Multiple Sclerosis and Tysabri, Part 2 - Ted Yednock

Science Communication Lab

Natalizumab improves mental and social health in a real-world MS cohort

Challenges and insights into anti-CD20 therapy for MS

Dr Paul Molyneux - Managing PML risk in patients treated with Natalizumab.

At the Limits - Leading Medical Education

My Treatment, My Decision

TYSABRI® (natalizumab)

Expert Insights on Managing Multiple Sclerosis: A Clinical Perspective [PART 2 of 4]

Aaron Boster MD